Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Is that your go to argument?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Post by MrMugsyon Apr 01, 2022 7:45pm
172 Views
Post# 34569107

Is that your go to argument?

Is that your go to argument?Currency and Corruption in LATAM - hahaha !
You think Sub-Saharan Africa was such a problem that Paladin couldn't find a buyer ?

Man - you really don't give people much credit down there. 
I know ... they're all coming to Florida for medical attention as you previously said ... right ?
And Biogen is bringing a $56,000 Alzheimer medication to LATAM to clean our clock ... right ?
Where do you get these brilliant ideas?

Even Goodman/Samira are willing to put the right controls in place to protect our interests.
Even Knight is willing to pay 350 people in Argentina to move our interests forward.

Glad we have Samira in charge - she's not as afraid of LATAM like you are.

You should go visit LATAM and maybe you wouldn't be so scared of it.

: )
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities